REG - Verici Dx PLC - Proposed US pricing for Tutivia™

Verici DxAnnouncement

05/06/2023 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230605:nRSE5717Ba&default-theme=true

RNS Number : 5717B  Verici Dx PLC  05 June 2023

Verici Dx plc

("Verici Dx" or the "Company")

 

Proposed US pricing for Tutivia™

Medicare proposed gapfill median rate of $2,650 per test

 

Verici Dx plc (AIM: VRCI), a developer of advanced clinical diagnostics for
organ transplant, announces that a gapfill median rate of $2,650 has been
proposed for Tutivia™ for kidney transplant rejection by the Centers for
Medicare & Medicaid Services ("CMS").

 

Medicare is a national health insurance program in the US that covers 63.9
million patients. Gapfill pricing is a method used by CMS to establish payment
rates for clinical laboratory tests under the Clinical Laboratory Fee Schedule
("CLFS") when no comparable test already exists on the CLFS.

 

The proposed rate was supported by the majority of Medicare Administrative
Contractor ("MAC") localities, including Palmetto GBA, the MAC that will
process future Medicare claims submitted for tests performed in Verici's
Tennessee laboratory. This proposed rate is currently open for public comment
before it is finalised later this year. Following finalisation, the price in
the CLFS is valid for a period of three years from 1 January 2024, after which
it is subject to further review.

 

Sara Barrington, Chief Executive Officer of Verici Dx, commented: "This is
another important milestone in our commercial strategy, and we are pleased the
majority of MAC localities have proposed pricing for our Tutivia™ tests
consistent with the resources required to develop and perform these tests. I
look forward to the pricing being finalised later this year and securing
reimbursement coverage in due course."

 

Enquiries:

 

 Verici Dx                                                www.v (http://www.vericidx.com) ericidx (http://www.vericidx.com) .com
                                                          (http://www.vericidx.com)
 Sara Barrington, CEO                                     Via Walbrook PR
 Julian Baines, Chairman

 Singer Capital Markets (Nominated Adviser & Broker)      Tel: +44 20 7496 3000
 Aubrey Powell / Sam Butcher

 Walbrook PR Limited                                      Tel: +44 20 7933 8780 or vericidx@walbrookpr.com
                                                          (mailto:renalytix@walbrookpr.com)
 Paul McManus / Stephanie Cuthbert /                      Mob: +44 7980 541 893 / +44 7796 794 663 /

 Sam Allen                                                07502 558 258

 

About Verici Dx plc www.vericidx.com (http://www.vericidx.com)

Verici Dx is a developer of a complementary suite of leading-edge tests
forming a kidney transplant platform for personalised patient and organ
response risk to assist clinicians in medical management for improved patient
outcomes. The underlying technology is based upon artificial intelligence
assisted transcriptomic analysis to provide RNA signatures focused upon the
immune response and other biological pathway signals critical for transplant
prognosis of risk of injury, rejection and graft failure from pre-transplant
to late stage.  The Company also has a mission to accelerate the pace of
innovation by research using the fully characterised data from the underlying
technology and collaboration with medical device, biopharmaceutical and data
science partners.

 

The foundational research was driven by a deep understanding of cell-mediated
immunity and is enabled by access to expertly curated collaborative studies in
highly informative cohorts in kidney transplant.

 

Verici Dx's two lead products are Tutivia™, a post-transplant test focused
upon acute cellular rejection, including sub-clinical rejection and
Clarava™, a pre-transplant prognosis test for the risk of early acute
rejection. These products seek to measure how a patient is likely to respond,
and is responding, to a kidney transplant. These products are underpinned by
extensive patented and published scientific research from the leading Mount
Sinai Medical Center, for which the Company holds an exclusive worldwide
licence.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCXZLFBXQLFBBX